Hackensack Meridian Mountainside Medical Center chosen for innovative MICRO 2
Hackensack Meridian Mountainside Medical Center in Montclair recently announced it was selected as a site for the Genetesis MICRO 2.0 Clinical Trial, a pioneering study focused on advancing non-invasive cardiac diagnostics in the evaluation of coronary microvascular dysfunction.
“Being chosen to participate in the Genetesis MICRO 2.0 Clinical Trial is a significant milestone for Mountainside Medical Center,” Tim O’Brien, CEO of Mountainside Medical Center, said. “This trial represents the future of cardiac diagnostics, and we are excited to be at the forefront of such groundbreaking research. Our involvement underscores our commitment to integrating the latest technological advancements into our patient care strategies.”
This trial will explore the potential of cutting-edge magnetocardiography technology to revolutionize the way cardiac conditions are diagnosed and managed, furthering the hospital’s mission to bring innovative and patient-centered care to the community.
“As a research coordinator, I am passionate about bringing innovative studies like the Genetesis MICRO 2.0 trial to our patients,” nurse Alyssa Stolarik, cardiovascular research coordinator, said. “This trial not only allows us to offer our patients access to cutting-edge diagnostics, but also positions Mountainside Medical Center as a leader in cardiovascular research. I am eager to see how this study will contribute to the future of cardiac care.”
The selection of Mountainside Medical Center as a site for the Genetesis MICRO 2.0 Clinical Trial highlights the institution’s dedication to advancing cardiac care through innovative research. By participating in this landmark trial, the medical center continues to lead the way in offering the most advanced diagnostic and treatment options to its patients.
